Literature DB >> 23710329

Treatment of borderline personality disorder and co-occurring anxiety disorders.

Melanie S Harned1, Helen R Valenstein.   

Abstract

Anxiety disorders are highly prevalent among individuals with borderline personality disorder, with comorbidity rates of up to 90%. Anxiety disorders have been found to reduce the likelihood of achieving remission from borderline personality disorder over time and to increase the risk of suicide and self-injury in this population. Evidence-based treatments for borderline personality disorder have not sufficiently focused on targeting anxiety disorders, and their effects on these disorders are either limited or unknown. Conversely, evidence-based treatments for anxiety disorders typically exclude suicidal, self-injuring, and seriously comorbid patients, thereby limiting their generalizability to individuals with borderline personality disorder. To address these limitations, recent research has begun to emerge focused on developing and evaluating treatments for individuals with co-occurring borderline personality disorder and anxiety disorders, specifically posttraumatic stress disorder (PTSD), with promising initial results. However, there is a need for additional research in this area, particularly studies evaluating the treatment of anxiety disorders among high-risk and complex borderline personality disorder patients.

Entities:  

Year:  2013        PMID: 23710329      PMCID: PMC3643080          DOI: 10.12703/P5-15

Source DB:  PubMed          Journal:  F1000Prime Rep        ISSN: 2051-7599


Introduction

Borderline personality disorder is a severe and complex psychological disorder characterized by long-term patterns of intense emotions, impulsive and self-destructive behaviors, and chaotic relationships. Borderline personality disorder is also associated with high rates of comorbidity. Individuals with borderline personality disorder meet criteria for an average of 3.0 to 3.4 current Axis I disorders (e.g. mood, anxiety, eating, psychotic, and substance use disorders) and 4.2 to 4.8 lifetime Axis I disorders [1,2]. Although emphasis is often placed on the comorbidity between borderline personality disorder and mood disorders, anxiety disorders are equally and highly prevalent, with approximately 75-90% of individuals with borderline personality disorder meeting criteria for at least one lifetime anxiety disorder [3-5]. Despite the negative prognostic significance of anxiety disorders on borderline personality disorder [6], there is a paucity of research examining effective treatments for these frequently co-occurring disorders, particularly among severe borderline personality disorder patients. The present review will describe the existing research in this area and make suggestions for future directions.

The prevalence, course, and impact of anxiety disorders in borderline personality disorder

Although the high rate of comorbidity between borderline personality disorder and PTSD has received the most theoretical and empirical attention, each of the anxiety disorders has been found to be prevalent among individuals with borderline personality disorder. Among borderline personality disorder inpatients, 88% meet criteria for a lifetime anxiety disorder, including PTSD (56%), panic disorder (48%), social anxiety disorder (46%), specific phobia (32%), obsessive compulsive disorder (16%), generalized anxiety disorder (14%), and agoraphobia (12%) [4]. Similarly, high rates of current and lifetime anxiety disorders have been found among borderline personality disorder outpatients [1], treatment-seeking individuals with borderline personality disorder [7], and community samples of borderline personality disorder individuals [5]. Anxiety disorders are more prevalent among borderline personality disorder patients than other clinical populations [1,4], and among women than men with borderline personality disorder [5,8]. Anxiety disorders also have a complex and variable course in borderline personality disorder, with high rates of remission (77-100%), recurrence (30-65%), and new onsets (15-45%) over 10 years of prospective follow-up [9,10]. Perhaps most critically, anxiety disorders are associated with a heightened risk of suicidal and non-suicidal self-injury among individuals with borderline personality disorder [11-18] and have been found to decrease the likelihood of achieving remission from borderline personality disorder over time [6].

The efficacy of borderline personality disorder treatments for co-occurring anxiety disorders

To date, there have been 14 randomized controlled trials (RCTs) that have examined the effects of borderline personality disorder treatments on anxiety, with all but one of these focused on general anxiety severity as opposed to specific anxiety disorder diagnoses (Table 1). The one study that has evaluated the effects of borderline personality disorder treatment on anxiety disorder diagnoses found that, among suicidal borderline personality disorder women in Dialectical Behavior Therapy, rates of remission from anxiety disorders ranged from 35-47% [2]. These remission rates did not differ from those found in the Community Treatment by Experts control condition (24-54%), and were lower than those found for mood, substance, and eating disorders in Dialectical Behavior Therapy (64-88%) [2]. The remaining 13 studies have examined general anxiety severity and have found mixed results. At post-treatment and/or follow-up, nine studies found significant decreases in anxiety [19-28], one study did not find a significant decrease [29], and three studies did not report pre-post changes [30-33]. Additionally, six studies found significant treatment differences in anxiety outcomes [19-22,26,27,33], whereas seven studies found no differences between treatments [23-25,28-32]. Although these studies generally indicate that treatment for borderline personality disorder is associated with a significant reduction in anxiety severity, it is unknown if or how these improvements are related to anxiety disorder diagnostic status. Of note, several borderline personality disorder treatments that have been examined in RCTs have not yet been evaluated in terms of their impact on anxiety outcomes, including Schema-Focused Therapy, Systems Training for Emotional Predictability and Problem Solving, Dynamic Deconstructive Psychotherapy, and General Psychiatric Management (see [34] for a review of these treatments).
Table 1.

Anxiety-related outcomes in randomized controlled trials of treatments for borderline personality disorder

StudySampleNSettingStudy lengthTreatmentsAnxiety measureAnxiety-related outcomes
Bateman et al.(1999; 2001)[19,20]Mixed genderwith BPD38Partial hospitaland outpatientTx: 1.5 yearsFu: 1.5 yearsMentalization basedtreatment; Treatmentas usualSpielbergerState-TraitAnxietyInventoryDuring treatment, state and trait anxiety significantly decreased in mentalizationbased treatment but not in treatment as usual. During follow-up, state anxietywas significantly lower in mentalization based treatment than in treatment asusual.
Bellino et al.(2006) [23]Mixed genderwith BPDand majordepression32OutpatientTx: 6 monthsInterpersonalpsychotherapy + fluoxetine;Clinical management +fluoxetineHamiltonAnxiety RatingScaleBoth treatments had a significant reduction in anxiety. There was no significantdifference between treatments.
Bellino et al.(2007) [22]Mixed genderwith BPDand majordepression26OutpatientTx: 6 monthsCognitive therapy;InterpersonalpsychotherapyHamiltonAnxiety RatingScaleBoth treatments had a significant reduction in anxiety. Cognitive therapy had asignificantly greater reduction in anxiety than interpersonal psychotherapy.
Bellino et al.(2010) [21]Mixed genderwith BPD44OutpatientTx: 8 monthsInterpersonalpsychotherapy adapted toBPD + fluoxetine; Clinicalmanagement + fluoxetineHamiltonAnxiety RatingScaleBoth treatments had a significant reduction in anxiety. Interpersonalpsychotherapy + fluoxetine had a significantly greater reduction in anxiety thanfluoxetine only.
Clarkin et al.(2007) [24]Mixed genderwith BPD90OutpatientTx: 1 yearTransference focusedpsychotherapy; Dialecticalbehavior therapy;Supportive therapyBrief SymptomInventoryAll three treatments had a significant reduction in anxiety. There was nosignificant difference between treatments.
Cottraux et al.(2009) [33]Mixed genderwith BPD65OutpatientTx: 1 yearFu: 1 yearCognitive therapy; Rogeriansupportive therapyBeck AnxietyInventoryThere was no significant difference between treatments for change in anxietyfrom baseline. However, at the 1-year follow-up, anxiety was significantly lowerin cognitive therapy than Rogerian therapy.
Davidsonet al. (2006;2010) [30,31]Mixed genderwith BPD106OutpatientTx: 1 yearFu: 1 yearand 6 yearsCognitive behavioraltherapy plus treatment asusual; Treatment as usualSpielbergerState-TraitAnxietyInventoryAt post-treatment, there was no significant difference on state or trait anxietybetween treatments. At the 1-year follow-up, cognitive behavioral therapy plustreatment as usual had significantly lower state anxiety than treatment as usual.At the 6 year follow-up, there was no significant difference between treatments.
Doering et al.(2010) [25]Women with BPD104OutpatientTx: 1 yearTransference-focusedtherapy; Communitytreatment by expertsSpielbergerState-TraitAnxietyInventoryBoth treatments had a significant reduction in anxiety. There was no significantdifference between treatments.
Gratz et al.(2006) [26]Self-harmingwomen withBPD22OutpatientTx: 3.5 monthsEmotion regulationgroup + treatment asusual; Treatment as usualDepressionAnxiety StressScalesThere was a significant reduction in anxiety in emotion regulation group +treatment as usual, but not treatment as usual.
Harned et al.(2008) [2]Women withBPD and recentand repeatedintentionalself-injury101OutpatientTx: 1 yearFu: 1 yearDialectical behaviortherapy; Communitytreatment by expertsLongitudinalIntervalFollow-UpEvaluationNo significant difference between treatments for rates of remission fromanxiety disorders.
Koons et al.(2001) [29]Womenveteranswith BPD20OutpatientTx: 6 monthsDialectical behaviortherapy; Treatment asusualHamiltonAnxiety RatingScaleNeither treatment had a significant change in anxiety.
Linehan et al.(1993) [32]Women withBPD39OutpatientTx: 1 yearFu: 1 yearDialectical behaviortherapy; Treatment asusualSocial AdjustmentScale –Self-ReportThere was no difference between treatments in anxious rumination at 6 and12 month follow-up.
Soler et al. (2009) [27]Mixed genderwith BPD60OutpatientTx: 3 monthsDialectical behaviortherapy-skills training only;Standard group therapyHamiltonAnxiety RatingScaleThere was a reduction in anxiety in dialectical behavior therapy-skills trainingonly but not standard group therapy.
Turner et al.(2000) [28]Mixed genderwith BPD24OutpatientTx: 1 yearDBT-oriented therapy;Client-centered therapyBeck AnxietyInventoryBoth treatments had a significant reduction in anxiety. There was no significantdifference between treatments.

BPD, Borderline personality disorder

BPD, Borderline personality disorder

The efficacy of anxiety disorder treatments for individuals with borderline personality disorder

Although numerous evidence-based treatments for anxiety disorders are available, borderline personality disorder patients, particularly those with a severe level of disorder, are likely to be excluded from these treatments due to suicidality, self-injurious behavior, and other co-occurring problems that are deemed primary or in need of immediate treatment [35,36]. As a result, few studies have evaluated the efficacy of anxiety disorder treatments among individuals with borderline personality disorder, and the available research is limited to PTSD treatment studies. Results from three RCTs of cognitive-behavioral treatments for PTSD indicate that patients with borderline personality disorder or borderline personality characteristics exhibited a comparable rate of improvement as patients without borderline personality disorder or borderline personality characteristics [37-39]. However, borderline personality disorder patients (11%) were less likely than those without borderline personality disorder (51%) to achieve good end-state functioning [37]. Importantly, each of these studies excluded patients with acute suicidality as well as one or more other problems common in severe borderline personality disorder (e.g. substance use disorder, recent self-injury). Although some research has evaluated the impact of personality disorders on treatment outcome for non-PTSD anxiety disorders [40,41], no studies have specifically evaluated the effect of borderline personality disorder. Thus, research on the use of anxiety disorder treatments among individuals with borderline personality disorder is limited by the small number of studies available, the exclusion of severe borderline personality disorder patients, and the lack of studies on anxiety disorders other than PTSD.

Recent advances in psychosocial treatments for borderline personality disorder and co-occurring anxiety disorders

Given the paucity of empirical data on the treatment of co-occurring borderline personality disorder and anxiety disorders, recent research has begun to emerge focused on developing and evaluating treatments for this population. To date, this research has focused exclusively on individuals with comorbid borderline personality disorder and PTSD. Harned and colleagues have developed a one-year outpatient treatment for suicidal and self-injuring individuals with borderline personality disorder and PTSD that integrates Dialectical Behavior Therapy with a modified version of Prolonged Exposure therapy for PTSD [42,43]. To date, this treatment has been evaluated in an open trial (n = 13) with results indicating that it is feasible and safe to administer, and is associated with large and significant improvements in PTSD (pre-post d = 1.4 − 1.7; remission rate = 60-72%), intentional self-injury, and a number of secondary outcomes [44]. Pabst and colleagues [45] conducted a feasibility trial of Narrative Exposure Therapy for women with borderline personality disorder and PTSD (n = 10). Treatment primarily occurred in an inpatient unit, lasted an average of 14 sessions, and excluded patients who were unwilling to consent to a no-suicide contract, had attempted suicide in the past eight weeks, or had other severe comorbidities. The treatment was associated with significant reductions in PTSD (g = 0.92) and several secondary outcomes. Finally, although not intended specifically for borderline personality disorder patients, Bohus and colleagues have developed a 12-week residential treatment for women with childhood sexual abuse-related PTSD plus a current diagnosis of major depression, eating disorder, substance use disorder, and/or at least four borderline personality disorder criteria. Individuals with a suicide attempt in the past four months are excluded. This treatment combines modified Dialectical Behavior Therapy and trauma-focused cognitive-behavioral approaches [46] and has been evaluated in an open trial (n = 29) [47] and an RCT (n = 74) [48], in which borderline personality disorder patients constituted 24-42% of the samples. Both studies have shown large and significant reductions in PTSD (d = 1.2 − 1.5; remission rate = 35-36%) and a number of secondary outcomes [47,48] with one study finding that results were comparable between patients with and without borderline personality disorder [48]. Although these treatments have shown promising results, more research is needed to replicate these findings using randomized controlled designs with larger samples of borderline personality disorder patients.

Future directions

Given the high rate of co-occurring anxiety disorders among borderline personality disorder patients, as well as the negative impact of these disorders on achieving remission from borderline personality disorder, it is imperative that additional research continues to evaluate how to effectively treat anxiety disorders among individuals with borderline personality disorder. To date, the available research has focused exclusively on evaluating treatments for PTSD among borderline personality disorder patients, and no research has yet evaluated treatments for other types of anxiety disorders in borderline personality disorder. In addition, with the exception of Dialectical Behavior Therapy, the impact of existing borderline personality disorder treatments on specific anxiety disorders has not been examined. As efforts to develop and evaluate treatments for co-occurring borderline personality disorder and anxiety disorders continue, attention should be paid to tailoring these treatments to borderline personality disorder patients with various levels of disorder. For example, it may be the case that existing, brief (9-12 week) anxiety disorder treatments can be implemented safely and effectively among borderline personality disorder patients with a mild level of disorder (e.g. those without suicidal and self-injurious behaviors or severe comorbidities) [37,38]. Borderline personality disorder patients with a moderate level of disorder (e.g. low risk non-suicidal self-injury without serious suicidality, significant but non-disabling deficits in interpersonal and emotion regulation skills) may benefit from longer (12-16 week) and/or more intensive (e.g. residential) sequential treatments that implement strategies from borderline personality disorder treatments (e.g. skills training) prior to targeting anxiety disorders [47-49]. Finally, longer-term treatment (e.g. one year) that provides integrated treatment for borderline personality disorder and anxiety disorders may be necessary for borderline personality disorder patients with a severe level of disorder (e.g. recent serious suicidal and/or self-injurious behaviors, severe comorbidities, disabling psychosocial impairment) [44]. Within this general research agenda, several important questions remain to be addressed. First, it will be important to develop empirically-derived criteria for determining when to target anxiety disorders among individuals with borderline personality disorder, particularly in the context of multiple other severe problems. For example, it is not yet clear whether anxiety disorders can be safely and effectively treated among borderline personality disorder patients who are actively engaging in non-suicidal self-injury. It is also possible that these readiness criteria may differ depending on the treatment setting (e.g. inpatient/residential versus outpatient), type of anxiety disorder (e.g. PTSD versus other diagnoses), and/or the relationship of anxiety disorder symptoms to suicidal and self-injurious behaviors. Finally, some research has begun to identify common factors underlying borderline personality disorder and anxiety disorders, including a tendency to experience negative emotions combined with efforts to try to alter or avoid these emotions [50-53]. The extant research suggests that borderline personality disorder treatments that address these common factors may be sufficient to facilitate improvements in general anxiety severity. However, additional research is needed to determine whether more targeted anxiety disorder treatment is necessary to achieve full remission from these disorders during treatment for borderline personality disorder.
  48 in total

1.  Treatment for PTSD related to childhood abuse: a randomized controlled trial.

Authors:  Marylene Cloitre; K Chase Stovall-McClough; Kate Nooner; Patty Zorbas; Stephanie Cherry; Christie L Jackson; Weijin Gan; Eva Petkova
Journal:  Am J Psychiatry       Date:  2010-07-01       Impact factor: 18.112

2.  Impact of co-occurring posttraumatic stress disorder on suicidal women with borderline personality disorder.

Authors:  Melanie S Harned; Shireen L Rizvi; Marsha M Linehan
Journal:  Am J Psychiatry       Date:  2010-09-01       Impact factor: 18.112

3.  Axis I diagnostic comorbidity and borderline personality disorder.

Authors:  M Zimmerman; J I Mattia
Journal:  Compr Psychiatry       Date:  1999 Jul-Aug       Impact factor: 3.735

4.  The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence.

Authors:  T H McGlashan; C M Grilo; A E Skodol; J G Gunderson; M T Shea; L C Morey; M C Zanarini; R L Stout
Journal:  Acta Psychiatr Scand       Date:  2000-10       Impact factor: 6.392

5.  Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; D Bradford Reich; Kenneth R Silk
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

6.  Treating co-occurring Axis I disorders in recurrently suicidal women with borderline personality disorder: a 2-year randomized trial of dialectical behavior therapy versus community treatment by experts.

Authors:  Melanie S Harned; Alexander L Chapman; Elizabeth T Dexter-Mazza; Angela Murray; Katherine A Comtois; Marsha M Linehan
Journal:  J Consult Clin Psychol       Date:  2008-12

7.  Axis I comorbidity of borderline personality disorder.

Authors:  M C Zanarini; F R Frankenburg; E D Dubo; A E Sickel; A Trikha; A Levin; V Reynolds
Journal:  Am J Psychiatry       Date:  1998-12       Impact factor: 18.112

8.  The impact of posttraumatic stress disorder on dysfunctional implicit and explicit emotions among women with borderline personality disorder.

Authors:  Nicolas Rüsch; Patrick W Corrigan; Martin Bohus; Thomas Kühler; Gitta A Jacob; Klaus Lieb
Journal:  J Nerv Ment Dis       Date:  2007-06       Impact factor: 2.254

Review 9.  The impact of personality disorders on treatment outcome of anxiety disorders: best-evidence synthesis.

Authors:  L Dreessen; A Arntz
Journal:  Behav Res Ther       Date:  1998-05

10.  Evaluating three treatments for borderline personality disorder: a multiwave study.

Authors:  John F Clarkin; Kenneth N Levy; Mark F Lenzenweger; Otto F Kernberg
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.